Only 11% of nearly 80 surveyed pharma and biotech companies had fully implemented AI and machine learning to support clinical trial activities as of late 2024, yet the industry conversation treats adoption as if it were already mainstream. That gap between rhetoric and operational reality is precisely what makes WCG’s 2026 Clinical Research Trends and Insights Report worth reading closely. Released this week, the report frames 2026 not as a year of breakthrough discovery but as a reckoning: the organizations that will perform best are those that have built preparedness into their infrastructure, not just their pitch decks.
The report organizes its analysis around four themes: AI and ML governance, site and investigator readiness, participant experience, and the operational demands of cell and gene therapies. On the AI front, the framing is notably disciplined. Rather than celebrating what algorithms can theoretically do, WCG positions AI as an emerging embedded capability that carries serious governance and trust obligations. That framing lands differently against the backdrop of the FDA’s January 2025 draft guidance on AI in regulatory decision-making, which signaled that the agency is watching how sponsors document, validate, and oversee AI-generated outputs. Enthusiasm without governance infrastructure is now a liability.
Site readiness gets equally direct treatment. ICON’s 2025 industry survey found that 55% of site respondents reported site activation taking five months or longer, with 39% saying those timelines had lengthened compared to two years prior. WCG’s answer is to reframe readiness as a continuous operational asset rather than a pre-trial checklist, a structural distinction that matters enormously for sponsors managing complex portfolios. Cell and gene therapy programs amplify every one of these pressures: longer follow-up windows, specialized logistics, narrow patient populations, and regulatory coordination demands that conventional site networks were never designed to absorb.
The participant experience thread ties the other three together. WCG draws a deliberate line between participant-centric design, a study built around patient convenience, and participant-driven research, where patient input actively shapes protocol decisions. That distinction has direct implications for retention rates and data quality, two variables that downstream regulatory submissions are acutely sensitive to. The single metric worth watching through 2026 is whether site activation timelines shorten as data-driven readiness assessments replace intuition-based site selection, because that compression is where operational theory meets revenue for every major CRO.
Source link: https://cms.centerwatch.com/insights/wcg-2026-clinical-research-trends-insights-report/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
